



**Beijing Baishideng BioMed Scientific Co., Ltd.,**  
Room 903, Building D, Ocean International Center,  
No.62 Dongsihuan Zhonglu,  
Chaoyang District, Beijing 100025, China  
Telephone: 0086-10-8538-1892 Fax: 0086-10-8538-1893  
E-mail: baishideng@wjgnet.com http: //www.wjgnet.com

---

**Name of Journal:** *World Journal of Gastroenterology*

**Ms:** wjg/2012/032881

**Title:** Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study.

**Reviewer code:** 0035871

**Science editor:** ke - vin

**Date sent for review:** 2012-06-12 13:08:01.0

**Date reviewed:** 2012-06-23 16:32:38.0

---

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: priority publishir	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language	<input type="checkbox"/> Existed	<input type="checkbox"/> Reject
<input checked="" type="checkbox"/> Grade C (Good)	polishing	<input checked="" type="checkbox"/> No records	<input type="checkbox"/> Withdraw
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade C: a great deal of	WJG Search:	
<input type="checkbox"/> Grade E (Poor)	language polishing	<input type="checkbox"/> Existed	
	<input type="checkbox"/> Grade D: rejected	<input checked="" type="checkbox"/> No records	

---

#### COMMENTS

##### COMMENTS TO AUTHORS:

This is an interesting and well done study regarding the treatment of celiac patients with an enzymatic approach. Even if the primary endpoint was not met, this study is of interest and warrant support for such an approach. My only question is the small number of patient.

Minor: in the abstract, first line, define AN-PEP instead of in the second line.



**Beijing Baishideng BioMed Scientific Co., Ltd.,**  
Room 903, Building D, Ocean International Center,  
No.62 Dongsihuan Zhonglu,  
Chaoyang District, Beijing 100025, China  
Telephone: 0086-10-8538-1892 Fax: 0086-10-8538-1893  
E-mail: baishideng@wjgnet.com http://www.wjgnet.com

---

**Name of Journal:** *World Journal of Gastroenterology*

**Ms:** wjg/2012/032881

**Title:** Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study.

**Reviewer code:** 0035596

**Science editor:** ke - vin

**Date sent for review:** 2012-07-26 16:32:06.0

**Date reviewed:** 2012-08-16 14:52:10.0

---

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: priority publishir	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language	<input type="checkbox"/> Existed	<input type="checkbox"/> Reject
<input checked="" type="checkbox"/> Grade C (Good)	polishing	<input checked="" type="checkbox"/> No records	<input type="checkbox"/> Withdraw
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade C: a great deal of	WJG Search:	
<input type="checkbox"/> Grade E (Poor)	language polishing	<input type="checkbox"/> Existed	
	<input type="checkbox"/> Grade D: rejected	<input checked="" type="checkbox"/> No records	

---

## COMMENTS

### COMMENTS TO AUTHORS:

The aim of the present study was to examined the the safety and efficacy of *Aspergillus niger* prolyl endoprotease (AN-PEP) to reduce the clinical response to gluten in patients with Coeliac Disease (CD). The safety study showed that AN-PEP was safe and well tolerated by patients with CD. However, the efficacy study showed a lack of clinical response due to an inappropriate gluten challenge mainly in the placebo group. The authors suggested that a longer gluten challenge may be necessary to induce a clinical response to gluten. It is perhaps that the cohort selected Marsh score 0 or 1 may not be be classified as CD. Why did the authors chose Marsh score of 0 and 1? A marsh score of 0 is not indicative of CD.

Overall this is a novel and original study and has provided some good evidence that AN-PEP may have some potential therapeutic effects in CD. It is worth publishing. The manuscript was well written with great detail. However, further clarification is needed;

(1) Was a washout of 2 week sufficient?

(2) Why chose Marsh score 0 and 1 as CD patients? Marsh score 0 have normal histology. This may be why you are see a lack of clinical response with the gluten challenge.